Torthaí cuardaigh - Meral Akdoğan
- 1 - 10 toradh as 10 á dtaispeáint
-
1
Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract de réir M. Kurt, Saša Kačar, İsmet Önal, Meral Akdoğan, İbrahim C. Haznedaroğlu
Foilsithe / Cruthaithe 2008Artigo -
2
-
3
Is there any link between atrial arrhythmias and inflammatory bowel disease? de réir Can, Güray, Ekmen, Nergis, Can, Hatice, Bayraktar, Muhammet Fatih, Demirkol, Muhammed Emin, Kayhan, Meral Akdoğan, Sasani, Hadi
Foilsithe / Cruthaithe 2021Téacs -
4
A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes de réir Kurtoğlu, Elçin Latife, Kayhan, Başak, Gül, Mehmet, Kayhan, Burçak, Kayhan, Meral Akdoğan, Karaca, Zeynal Mete, Yeşilada, Elif, Yılmaz, Sezai
Foilsithe / Cruthaithe 2019Téacs -
5
Prevalence and characteristics of bone disease in cirrhotic patients de réir Gokcan, Hale, Kayhan, Meral Akdogan, Demir, Sibel Ozbudak, Kacar, Sabite, Cam, Pinar, Kaplan, Mustafa, Daylak, Rabia, Oztuna, Derya, Kuran, Sedef Özdal, Ari, Derya
Foilsithe / Cruthaithe 2020Téacs -
6
Tp‐e Interval, Tp‐e/QTc Ratio, and Fragmented QRS Are Correlated with the Severity of Liver Cirrhosis de réir Akboga, Mehmet Kadri, Yuksel, Mahmut, Balci, Kevser Gulcihan, Kaplan, Mustafa, Cay, Serkan, Gokbulut, Volkan, Yayla, Cagri, Ertem, Ahmet Goktug, Ayhan, Meral Akdogan, Topaloglu, Serkan, Aras, Dursun
Foilsithe / Cruthaithe 2016Téacs -
7
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels de réir Vincent Rijckborst, Bettina E. Hansen, Yılmaz Çakaloğlu, Péter Ferenci, Fehmı Tabak, Meral Akdoğan, Krzysztof Simon, Ulus Salih Akarca, Robert Flisiak, Elke Verhey, Anneke J. van Vuuren, Charles A. Boucher, Martijn J. ter Borg, Harry L.A. Janssen
Foilsithe / Cruthaithe 2010Artigo -
8
Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis de réir Hasan Eruzun, Lars Bossen, Dilara Turan Gökçe, İlkay Ergenç, Zekiye Nur Harput, Neslihan Güneş Aydemir, Meral Akdoğan Kayhan, Hasan Basri Yapıcı, Tarik Dogan, Peter Holland‐Fischer, Jesper Bach Hansen, Yusuf Yılmaz, Orhan Sezgın, Haydar Adanır, Ahmet Bektaş, Henning Grønbæk
Foilsithe / Cruthaithe 2025Artigo -
9
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2) de réir Markus Peck‐Radosavljevic, Krzysztof Simon, A. Iacobellis, Tarek Hassanein, Zeid Kayali, Albert Tran, Mihály Makara, Ziv Ben Ari, Marius Braun, Paul Mitruț, Sheng‐Shun Yang, Meral Akdoğan, Mario Pirisi, Ajay Duggal, Toshimitsu Ochiai, Tomoko Motomiya, Takeshi Kano, Tsutae Den Nagata, Nezam H. Afdhal
Foilsithe / Cruthaithe 2019Artigo -
10
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) de réir Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld, Ning‐Ping Zhang, Qin Zhang, Fehmı Tabak, Adrian Streinu‐Cercel, Jiyao Wang, Ramazan İdilman, Hendrik W. Reesink, Mircea Diculescu, Krzysztof Simon, M Voiculescu, Meral Akdoğan, Włodzimierz Mazur, Jurriën G.P. Reijnders, Elke Verhey, Bettina E. Hansen, Harry L.A. Janssen
Foilsithe / Cruthaithe 2014Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Internal medicine
Medicine
Gastroenterology
Chronic hepatitis
Confidence interval
HBeAg
HBsAg
Hepatitis B
Hepatitis B virus
Immunology
Randomized controlled trial
Ribavirin
Surgery
Virus
Adverse effect
Alternative medicine
Anastomosis
Billroth II
Blood transfusion
Cancer
Chronic liver disease
Cirrhosis
Clinical endpoint
Cohort
Cohort study
Combination therapy
Danish
Endoscopy
Entecavir
Environmental health